Pennsylvania is currently home to 3295 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
NCT05568680
Recruiting
This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Ovarian Cancer, Cholangiocarcinoma Recurrent, Mesothelioma, Malignant
Register for Updates
Ribociclib and Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT05467891
Recruiting
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Penn State Cancer Institute, Hershey, Pennsylvania
Conditions: Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Register for Updates
Cephea Early Feasibility Study
NCT05061004
Recruiting
The objective of this study is to evaluate the preliminary safety and effectiveness of the Cephea Mitral Valve System for the treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) in whom transcatheter therapy is deemed more appropriate than open heart surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Allegheny General Hospital - ASRI, Pittsburgh, Pennsylvania
Conditions: Mitral Regurgitation
Register for Updates
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age
NCT06864143
Recruiting
The purpose of this study is to evaluate the immunogenicity, reactogenicity, and safety, of mRNA-1083 multicomponent influenza and COVID-19 vaccine in adults ≥18 to \<65 years of age.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/19/2025
Locations: DM Clinical Research - Philadelphia, Philadelphia, Pennsylvania
Conditions: Influenza, SARS-CoV-2
Register for Updates
Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
NCT06080698
Recruiting
The Gram-negative bloodstream infection Oral Antibiotic Therapy trial (The GOAT Trial) is a multi-center, randomized clinical trial that hypothesizes that early transition to oral antibiotic therapy for the treatment of Gram-Negative BloodStream Infection (GN-BSI) is as effective but safer than remaining on intravenous (IV) antibiotic therapy for the duration of treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Gram-negative Bacteremia
Register for Updates
SKIP for PA Study: Team and Leadership Level Implementation Support for Collaborative Care
NCT04946253
Recruiting
In a prior application (MH064372), the investigators' treatment research program (Services for Kids In Primary-care, SKIP) developed and tested a chronic care model-based intervention, called Doctor Office Collaborative Care (DOCC), that was found to be effective in the management of childhood behavior problems and comorbid ADHD. In the "SKIP for PA Study", the investigators propose to conduct a randomized clinical trial to evaluate the effects of team- and practice leadership-level implementati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Drexel University, Philadelphia, Pennsylvania
Conditions: Child Behavior Problem, Attention Deficit and Disruptive Behavior Disorders
Register for Updates
Massage Impact on Sleep in Pediatric Oncology
NCT06892158
Recruiting
This study aims to determine the impact of massage therapy for pediatric patients receiving intensive chemotherapy or stem cell transplant (SCT).
Gender:
ALL
Ages:
Between 12 years and 21 years
Trial Updated:
03/18/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Cancer, Pediatric Cancer, Chemotherapy Effect, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Pediatric, Hematopoietic Stem Cell Transplantation (HSCT)
Register for Updates
Impact of Depression on Thermoregulation
NCT06805851
Recruiting
The purpose of this study is to determine if, compared to non-depressed adults, differences exist in skin blood flow and sweating responses to passive heat stress in adults with clinically diagnosed depression, those with depression who are prescribed and taking SSRIs and those with depression who are prescribed and taking SNRIs.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
03/18/2025
Locations: Noll Laboratory, University Park, Pennsylvania
Conditions: Depression, Selective Serotonin Reuptake Inhibitor
Register for Updates
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma in Situ
NCT06218303
Recruiting
Post-menopausal women with biopsy-proven DCIS will be enrolled into two cohorts. One cohort will receive neoadjuvant therapy with an aromatase inhibitor alone for about 12 weeks prior to surgery at 12 weeks. The second cohort will receive neoadjuvant therapy with an aromatase inhibitor and MUC1 vaccination (MUC1 peptide + Hiltonol®) pre-operatively at baseline, and weeks 2 and 10, followed by surgery at about 12 weeks. Patients in the vaccine cohort will be offered an optional boost vaccine 6 mo... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: UPMC Magee Womens Hospital, Pittsburgh, Pennsylvania
Conditions: Ductal Carcinoma in Situ
Register for Updates
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults with Gorlin Syndrome
NCT06050122
Recruiting
The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use. People who take part will apply either Patidegib Gel 2% or a Vehicle Gel (with no active drug substance) to their face twice a day for a year (12 months). The number of new BCCs on the face will be compared between those who used Patidegib Gel 2% or Vehicle Gel after 12 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Penn State Hershey Medical Center, Hershey, Pennsylvania
Conditions: Gorlin Syndrome
Register for Updates
GetUp&Go: a Randomized Controlled Trial of an Intervention to Enhance Physical Activity After TBI
NCT06028334
Recruiting
The goal of this clinical trial is to evaluate GetUp\&Go, a program for promoting increased physical activity in individuals at least 6 months post moderate-to-severe traumatic brain injury. GetUp\&Go is a remotely delivered 10-week program that includes one-on-one sessions with a therapist and a mobile health application (RehaBot). The main question is whether participants in the 10-week GetUp\&Go program increase their physical activity, and exhibit associated benefits in mental and physical... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Moss Rehabilitation Research Institute, Elkins Park, Pennsylvania
Conditions: Traumatic Brain Injury
Register for Updates
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
NCT06022029
Recruiting
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibitor in patients with advanced solid tumors and lymphomas.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Allegheny Health Network, Pittsburgh, Pennsylvania
Conditions: Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence
Register for Updates